Click here to close now.




















Welcome!

News Feed Item

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Sickle Cell Disease Global Clinical Trials Review, H2, 2014" provides data on the Sickle Cell Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sickle Cell Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sickle Cell Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Sickle Cell Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Sickle Cell Disease 25
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Sickle Cell Disease Therapeutics Clinical Trials 33
Prominent Drugs 35
Latest Clinical Trials News on Sickle Cell Disease 36
Jun 16, 2014: Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
Novartis AG 37
Clinical Trial Overview of Novartis AG 37
Eli Lilly and Company 38
Clinical Trial Overview of Eli Lilly and Company 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Prolong Pharmaceuticals 40
Clinical Trial Overview of Prolong Pharmaceuticals 40
HemaQuest Pharmaceuticals, Inc. 41
Clinical Trial Overview of HemaQuest Pharmaceuticals, Inc. 41
Selexys Pharmaceuticals Corporation 42
Clinical Trial Overview of Selexys Pharmaceuticals Corporation 42
Ikaria Inc. 43
Clinical Trial Overview of Ikaria Inc. 43
Emmaus Life Sciences, Inc. 44
Clinical Trial Overview of Emmaus Life Sciences, Inc. 44
Baxter International Inc. 45
Clinical Trial Overview of Baxter International Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Heart, Lung, and Blood Institute 46
Clinical Trial Overview of National Heart, Lung, and Blood Institute 46
Assistance Publique - Hopitaux de Paris 49
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 49
HaEmek Medical Center 50
Clinical Trial Overview of HaEmek Medical Center 50
Cincinnati Children's Hospital Medical Center 51
Clinical Trial Overview of Cincinnati Children's Hospital Medical Center 51
Duke University 52
Clinical Trial Overview of Duke University 52
Emory University 53
Clinical Trial Overview of Emory University 53
National Institutes of Health Clinical Center 54
Clinical Trial Overview of National Institutes of Health Clinical Center 54
Baylor College of Medicine 55
Clinical Trial Overview of Baylor College of Medicine 55
Children's Hospital & Research Center Oakland 56
Clinical Trial Overview of Children's Hospital & Research Center Oakland 56
Five Key Clinical Profiles 57
Appendix 99
Abbreviations 99
Definitions 99
Research Methodology 100
Secondary Research 101
About GlobalData 101
Contact Us 101
Disclaimer 101
Source 102

List of Tables
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Sickle Cell Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Sickle Cell Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 37
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 38
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 39
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Prolong Pharmaceuticals, 2014* 40
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HemaQuest Pharmaceuticals, Inc., 2014* 41
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Selexys Pharmaceuticals Corporation, 2014* 42
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ikaria Inc., 2014* 43
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emmaus Life Sciences, Inc., 2014* 44
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2014* 45
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 46
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 49
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HaEmek Medical Center, 2014* 50
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Cincinnati Children's Hospital Medical Center, 2014* 51
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 52
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 53
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institutes of Health Clinical Center, 2014* 54
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 55
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Hospital & Research Center Oakland, 2014* 56

List of Figures
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
GlobalData Methodology 100

Read the full report:
Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
SYS-CON Events announced today that the "Second Containers & Microservices Expo" will take place November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Scrum Alliance has announced the release of its 2015 State of Scrum Report. Almost 5,000 individuals and companies worldwide participated in this year's survey. Most organizations in the market today are still leading and managing under an Industrial Age model. Not only is the speed of change growing exponentially, Agile and Scrum frameworks are showing companies how to draw on the full talents and capabilities of those doing the work in order to continue innovating for success.
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
Between the compelling mockups and specs produced by your analysts and designers, and the resulting application built by your developers, there is a gulf where projects fail, costs spiral out of control, and applications fall short of requirements. In his session at @DevOpsSummit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, presented a new approach where business and development users collaborate – each using tools appropriate to their goals and expertise – to build mocku...
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
Graylog, Inc., has added the capability to collect, centralize and analyze application container logs from within Docker. The Graylog logging driver for Docker addresses the challenges of extracting intelligence from within Docker containers, where most workloads are dynamic and log data is not persisted or stored. Using Graylog, DevOps and IT Ops teams can pinpoint the root cause of problems to deliver new applications faster and minimize downtime.
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.